Predicting Immuno-Metabolic Complications After Allogeneic Hematopoietic Cell Transplant with the Cytokine Interleukin-33 (IL-33) and its Receptor Serum-Stimulation 2 (ST2) [0.03%]
使用细胞因子白介素-33（IL-33）及其受体血清刺激2（ST2）预测同种异基因造血细胞移植后的免疫代谢并发症
Uttam K Rao,Brian G Engelhardt
Uttam K Rao
Patients undergoing allogeneic hematopoietic cell transplantation (HCT) are at risk for numerous acute and long-term complications from this procedure. Post-transplant diabetes mellitus (PTDM) is a common but under-recognized problem. Simil...
Cold Agglutinin Disease [0.03%]
冷凝集素病
Amy P Gabbard,Garrett S Booth
Amy P Gabbard
Cold agglutinin disease (CAD) is an uncommon form of cold autoimmune hemolytic anemia (AIHA). It should be considered in the differential diagnosis of elderly patients with unexplained chronic anemia presenting with or without cold-induced ...
Bortezomib, Lenalidomide and Dexamethasone as Induction Therapy Prior to Autologous Transplantation in Multiple Myeloma: The More Is Likely the Better [0.03%]
自体移植前多发性骨髓瘤中使用硼替佐米，来那度胺和地塞米松进行诱导治疗：多多益善
Mohamad Mohty,Florent Malard,Ali Bazarbachi
Mohamad Mohty
Comparison of Conventional Cyclophosphamide versus Fludarabine-Based Conditioning in High-Risk Aplastic Anemia Patients Undergoing Matched-Related Donor Transplantation [0.03%]
高危再生障碍性贫血行匹配相关供者移植患者中传统环磷酰胺与氟达拉滨预处理方案的比较研究
Raheel Iftikhar,Qamar Un Nisa Chaudhry,Tariq Mehmood Satti et al.
Raheel Iftikhar et al.
Allogeneic stem cell transplant for high-risk aplastic anemia (AA) yields inferior results using conventional cyclophosphamide (CY)-based conditioning. The use of fludarabine (Flu)-based regimens has resulted in improved outcomes in high-ri...
The CD34+ Cell Dose Matters in Hematopoietic Stem Cell Transplantation with Peripheral Blood Stem Cells from Sibling Donors [0.03%]
同胞捐献的外周血干细胞移植物中CD34+细胞的数量在血液干细胞移植中起重要作用
M Remberger,B Grønvold,M Ali et al.
M Remberger et al.
The effect of CD34+ cell dose in allogeneic hematopoietic stem cell transplantation (HSCT) on overall survival (OS) and incidence of acute and chronic graft-versus-host disease (GvHD) has not been established and few studies have been perfo...
Repeat Endoscopy Affects Patient Management in Gastrointestinal Graft- Versus-Host Disease [0.03%]
胃肠道移植物抗宿主病的内镜复查影响患者的治疗管理
Ehsan Shabbir,Umar Farooq,Burhan Yanes et al.
Ehsan Shabbir et al.
Graft versus host disease (GVHD) of the gut is associated with significant morbidity and mortality after allogeneic hematopoietic cell transplant (allo-HCT). No guidelines exist regarding repeat endoscopy after failure of first-line treatme...
Maintenance Strategies Post-Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma [0.03%]
自体干细胞移植治疗新诊断多发性骨髓瘤后的维持策略
Sarah A Bird,Graham H Jackson,Charlotte Pawlyn
Sarah A Bird
Multiple myeloma, the second most common hematological malignancy worldwide, has demonstrated dramatic improvements in outcome in the last decade. In newly diagnosed patients, induction chemotherapy followed by autologous stem cell transpla...
Haploidentical Hematopoietic Stem Cell Transplantation Followed by 'Post-Cyclophosphamide': The Future of Allogeneic Stem Cell Transplant [0.03%]
单倍型相合造血干细胞移植序贯“后环磷酰胺”方案：异基因干细胞移植的未来方向
Samuel Cytryn,Maher Abdul-Hay
Samuel Cytryn
Allogeneic hematopoietic cell transplant (Allo-HCT) is a potentially curative therapy for many malignant and nonmalignant hematological diseases. However, a suitable human leukocyte antigens (HLAs)-matched donor may not be available when th...
Practicing Clinical Hematology During the COVID-19 Outbreak: A Challenge Like No Other [0.03%]
COVID-19疫情期间的临床血液病学实践：一场前所未有的挑战
Mohamad Mohty,Arnon Nagler,Bipin Savani
Mohamad Mohty
Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma [0.03%]
多发性骨髓瘤患者初次诊断时使用多柔比星，环磷酰胺，硼替佐米，地塞米松和来那度胺后进行硼替佐米巩固治疗的安全性和有效性研究
Kristian T Andersen,Maja Hinge,Agoston Gyula Szabo et al.
Kristian T Andersen et al.